Osborne Partners Capital Management LLC Reduces Stock Position in Pfizer Inc. $PFE

Osborne Partners Capital Management LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 19.5% during the first quarter, Holdings Channel.com reports. The fund owned 108,581 shares of the biopharmaceutical company’s stock after selling 26,270 shares during the period. Osborne Partners Capital Management LLC’s holdings in Pfizer were worth $3,049,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Leelyn Smith LLC raised its stake in shares of Pfizer by 5.5% during the first quarter. Leelyn Smith LLC now owns 118,078 shares of the biopharmaceutical company’s stock valued at $3,316,000 after acquiring an additional 6,168 shares during the last quarter. BIP Wealth LLC boosted its holdings in shares of Pfizer by 35.4% during the first quarter. BIP Wealth LLC now owns 19,950 shares of the biopharmaceutical company’s stock worth $560,000 after purchasing an additional 5,217 shares during the period. Baer Investment Advisory LLC bought a new stake in shares of Pfizer in the first quarter worth about $452,000. Canal Capital Management LLC purchased a new position in Pfizer during the 1st quarter valued at about $334,000. Finally, 4WEALTH Advisors Inc. increased its holdings in Pfizer by 4.1% during the 1st quarter. 4WEALTH Advisors Inc. now owns 16,516 shares of the biopharmaceutical company’s stock valued at $459,000 after purchasing an additional 650 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Guggenheim upped their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Finally, UBS Group restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Down 0.1%

PFE stock opened at $24.29 on Friday. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a market capitalization of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The business’s 50 day moving average price is $25.63 and its two-hundred day moving average price is $26.23. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the business posted $0.92 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.